BLS Pharmaceuticals (ASX:BLS) Delivers Record FY26 Revenue and Earnings Through International Expansion

Aditi Sarkar

06 November 2026 10:34 PM AEDT

BLS Pharmaceuticals (ASX:BLS) Delivers Record FY26 Revenue and Earnings Through International Expansion

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

BLS Pharmaceuticals recorded FY26 Revenue of AUD 74.2 million, rising 161%, alongside adjusted EBITDA of AUD 19 million for year.
Adjusted EBITDA increased 171% to AUD 19 million as the company expanded its pharmaceutical Manufacturing and international distribution footprint substantially.
The company secured a two year AUD 50 million Supply agreement with Germany based ADREXpharma, advancing its international commercial operations.
BLS completed its rebrand from Bioxyne Limited in June 2026 and began trading under its new ticker in July 2026.

BLS Pharmaceuticals Limited (ASX:BLS), formerly known as Bioxyne Limited (ASX:BXN), is an Australian pharmaceutical company focused on the manufacture, development, and commercialisation of regulated therapeutic products and active pharmaceutical ingredients (APIs). The company operates GMP-licensed manufacturing facilities in Australia and is building a Facility in Scotland, with distribution and supply relationships across Australia, the UK, Germany, and Latin America. BLS Pharmaceuticals' FY26 results for the year ended 30 June 2026 were released on 31 August 2026.

Record Revenue and Earnings

BLS Pharmaceuticals reported FY26 revenue of $74.2 million, up 161% from $29.3 million in FY25. The growth reflected the rapid scaling of the company's pharmaceutical manufacturing and distribution platform, including significant volumes supplied under international contracts. Adjusted EBITDA surged 171% to $19.0 million, achieving an adjusted EBITDA Margin of 26% — in line with the company's FY26 guidance range. NPAT was $15.4 million (+214%), with an operating EBITDA margin of 22.8%. The final quarter (Q4 FY26) was the company's strongest, with quarterly revenue of $22.5 million (+5% on Q3), the highest in company history. Net Operating Cash Flow was positive at $5.4 million, and BLS ended FY26 with $13.3 million in cash and no significant net Debt concerns, having raised Equity at various points during its growth phase.

International Expansion and Key Contracts

BLS's growth has been driven by international market penetration across multiple geographies. The company secured a two-year, $50 million pharmaceutical supply agreement with ADREXpharma, a Germany-based pharmaceutical distribution company, one of the largest contracts in BLS's history. The company also began first international supply to Costa Rica during FY26 and continued to build its UK and European presence through its Scottish manufacturing facility, expected to complete by end of 2026. BLS sources pharmaceutical raw materials and APIs from a global supply chain and operates GMP-certified facilities that give it access to regulated pharmaceutical markets. During FY26, the company rebranded from Bioxyne Limited to BLS Pharmaceuticals Limited, with Shareholder approval at the 19 June 2026 General Meeting and commencement of trading under the new ASX ticker BLS on 7 July 2026.

FY27 Outlook and Strategic Direction

BLS reaffirmed its FY27 guidance of $105–115 million in revenue and an adjusted EBITDA margin of 23–26% at its Q1 FY27 quarterly update (released 15 October 2026). Net operating cash flow in Q1 FY27 was $6.3 million, and the company had $12.7 million in cash at 30 September 2026. BLS was added to the S&P/ASX All Ordinaries index effective 21 September 2026, following the September quarterly review by S&P Dow Jones Indices. The company's GMP manufacturing facility in Scotland is targeted for completion by end of 2026, adding capacity and international market access. BLS's estimated annual revenue capacity from its facilities exceeds $250 million, providing significant scope for further growth through increased utilisation.

Stock Price Information

Shares in BLS Pharmaceuticals Limited (ASX:BLS) rose approximately 11% on the day of its Q4 FY26 trading update (27 July 2026), trading around $0.935. The company completed its rebrand from Bioxyne Limited and commenced trading under the new ASX Code BLS on 7 July 2026. As of 6 November 2026, BLS shares were trading on the ASX. Investors should refer to ASX announcements at www.asx.com.au and Investor relations at www.blspharma.com for current pricing and guidance updates.

FAQs

Q: What was Bioxyne Limited and why did it rebrand to BLS Pharmaceuticals?

A: Bioxyne Limited was an Australian life sciences company that pivoted its strategy in recent years toward pharmaceutical manufacturing and international distribution. As the business grew into a GMP-licensed pharmaceutical manufacturer with operations across Australia, the UK, Germany, and Latin America, management determined that the Bioxyne name no longer reflected the company's activities or market positioning. Shareholders approved the rebrand to BLS Pharmaceuticals Limited at the General Meeting on 19 June 2026, with ASIC registration and the new ASX code BLS commencing on 7 July 2026. The rebrand aligned the company's corporate identity with its GMP-manufacturing operations and pharmaceutical focus.

Q: What is ADREXpharma and what does the $50 million agreement involve?

A: ADREXpharma is a Germany-based pharmaceutical distribution company. BLS Pharmaceuticals secured a two-year pharmaceutical supply agreement with ADREXpharma during FY26, with an estimated contract value of $50 million. The agreement involves BLS supplying pharmaceutical products from its Australian GMP-licensed manufacturing facilities to ADREXpharma for distribution in the European market. This contract is one of the largest in BLS's history and is a key contributor to its FY27 revenue guidance of $105–115 million. It reflects the company's strategy of leveraging its Australian manufacturing capabilities to supply regulated pharmaceutical markets in Europe and beyond.

Q: What is BLS Pharmaceuticals' FY27 guidance?

A: BLS Pharmaceuticals reaffirmed at its Q1 FY27 update (released 15 October 2026) guidance of $105–115 million in revenue and an adjusted EBITDA margin of 23–26% for the full year FY27 (ending 30 June 2027). This represents significant growth from FY26's $74.2 million revenue, driven by the full-year contribution of the ADREXpharma agreement, expanded international supply into Costa Rica and other markets, and ongoing ramp-up of the Scottish manufacturing facility. The company estimates its manufacturing facilities have capacity for more than $250 million in annual revenue, providing a runway for further growth beyond FY27.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.